Consistent with these findings, a phase I/II clinical trial, performed on 10 disease-free HLA-A2+ melanoma patients, has proven that vaccination with Melan-A and gp100 peptides in combination with DTIC (administered one day before vaccine inoculation) results in an improved cellular immune response as compared with vaccination alone and prevents melanoma relapse [57]. The gene discussed is MLANA; the disease is melanoma.